Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
20 studies found for:    Open Studies | "Urethral Diseases"
Show Display Options
Download search resultsDownload the search results for:
Open Studies | "Urethral Diseases" (20 records)
Download Content:
Zip file readers with free trial periods: WinZip or PKZip
Rank Status Study
1 Unknown  Effect of Mitomycin C on Urethral Stricture Recurrence After Internal Urethrotomy
Condition: Urethral Stricture
Interventions: Procedure: Internal urethrotomy;   Drug: Mitomycin C -  local injection
2 Recruiting Functional Outcome of Urethral Reconstructive Surgery
Condition: Urethral Stricture
Interventions: Procedure: end-to-end urethroplasty;   Procedure: substitution urethroplasty (buccal mucosa);   Procedure: substitution urethroplasty (pedicled skin flap)
3 Recruiting Gemcitabine, Carboplatin, and Lenalidomide for Treatment of Advanced/Metastatic Urothelial Cancer and Other Solid Tumors
Conditions: Urethral Neoplasms;   Neoplasms, Urethral;   Ureter Cancer;   Cancer of the Urethra;   Urethral Cancer
Interventions: Drug: Gemcitabine;   Drug: Carboplatin;   Drug: Lenalidomide
4 Recruiting Chronic Inflammatory Condition of the Male Genital Tract
Condition: Urethritis
Intervention: Other: Sperm sample
5 Unknown  Efficiency of Cold vs. Laser Internal Urethrotomy Treatment of Urethral Strictures
Condition: Urethral Strictures
Intervention: Procedure: Internal Urethrotomy
6 Recruiting Afatinib in Advanced Refractory Urothelial Cancer
Conditions: Distal Urethral Cancer;   Proximal Urethral Cancer;   Recurrent Bladder Cancer;   Recurrent Urethral Cancer;   Stage III Bladder Cancer;   Stage III Urethral Cancer;   Stage IV Bladder Cancer;   Stage IV Urethral Cancer;   Ureter Cancer
Interventions: Drug: afatinib dimaleate;   Other: laboratory biomarker analysis
7 Not yet recruiting Scandinavian Urethroplasty Study
Condition: Urethral Stricture
Interventions: Procedure: End-to-end;   Procedure: Graft
8 Unknown  Sunitinib Malate in Treating Patients With Locally Recurrent, Locally Advanced, Unresectable, or Metastatic Urinary Tract Cancer
Conditions: Bladder Cancer;   Transitional Cell Cancer of the Renal Pelvis and Ureter;   Urethral Cancer
Interventions: Drug: sunitinib malate;   Other: immunohistochemistry staining method;   Other: laboratory biomarker analysis;   Other: pharmacological study;   Procedure: quality-of-life assessment
9 Recruiting Standardized Prenatal Clinical Care for LUTO
Condition: Urethral Obstruction
Intervention: Procedure: Fetal Intervention for LUTO
10 Recruiting Time to Eradication of Mycoplasma Genitalium and Chlamydia Trachomatis After Treatment Commenced
Conditions: Urethritis;   Cervicitis;   Genital Mycoplasma Infection;   Chlamydia Trachomatis
Interventions: Drug: Azithromycin;   Drug: Doxycycline;   Drug: lymecycline
11 Unknown  Diagnosis of Bladder Outlet Obstruction Using Dynamic Urine Vibration "Holter" in Comparison to Pressure Flow Study
Condition: Bladder Outlet Obstruction
Intervention: Device: Dynamic Urine Vibration "Holter"
12 Recruiting Eribulin Mesylate in Treating Patients With Locally Advanced or Metastatic Cancer of the Urothelium and Kidney Dysfunction
Conditions: Distal Urethral Carcinoma;   Infiltrating Bladder Urothelial Carcinoma Associated With Urethral Carcinoma;   Metastatic Urothelial Carcinoma of the Renal Pelvis and Ureter;   Proximal Urethral Carcinoma;   Recurrent Bladder Carcinoma;   Recurrent Urethra Carcinoma;   Recurrent Urothelial Carcinoma of the Renal Pelvis and Ureter;   Regional Urothelial Carcinoma of the Renal Pelvis and Ureter;   Stage III Bladder Cancer;   Stage III Urethral Cancer;   Stage IV Bladder Cancer;   Stage IV Urethral Cancer;   Ureter Carcinoma
Interventions: Drug: Eribulin Mesylate;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study
13 Unknown  An Open Label Study to Measure Efficacy of Fesoterodine (Toviaz) Post Surgery for Benign Prostatic Hyperplasia
Condition: Bladder Outlet Obstruction
Intervention: Drug: Toviaz (Fesoterodine)
14 Recruiting Cabozantinib for Advanced Urothelial Cancer
Conditions: Urethral Neoplasms;   Ureteral Neoplasms;   Urinary Bladder Neoplasms;   Kidney Neoplasms
Intervention: Drug: Cabozantinib
15 Recruiting Family Caregiver Palliative Care Intervention in Supporting Caregivers of Patients With Stage II-IV Gastrointestinal, Gynecologic, and Urologic Cancers
Conditions: Healthy, no Evidence of Disease;   Localized Transitional Cell Cancer of the Renal Pelvis and Ureter;   Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter;   Psychosocial Effects of Cancer and Its Treatment;   Recurrent Bladder Cancer;   Recurrent Cervical Cancer;   Recurrent Colon Cancer;   Recurrent Gastric Cancer;   Recurrent Ovarian Epithelial Cancer;   Recurrent Ovarian Germ Cell Tumor;   Recurrent Pancreatic Cancer;   Recurrent Rectal Cancer;   Recurrent Renal Cell Cancer;   Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter;   Recurrent Urethral Cancer;   Recurrent Uterine Sarcoma;   Regional Transitional Cell Cancer of the Renal Pelvis and Ureter;   Stage II Bladder Cancer;   Stage II Renal Cell Cancer;   Stage II Urethral Cancer;   Stage IIA Cervical Cancer;   Stage IIA Colon Cancer;   Stage IIA Gastric Cancer;   Stage IIA Ovarian Epithelial Cancer;   Stage IIA Ovarian Germ Cell Tumor;   Stage IIA Pancreatic Cancer;   Stage IIA Rectal Cancer;   Stage IIA Uterine Sarcoma;   Stage IIB Cervical Cancer;   Stage IIB Colon Cancer;   Stage IIB Gastric Cancer;   Stage IIB Ovarian Epithelial Cancer;   Stage IIB Ovarian Germ Cell Tumor;   Stage IIB Pancreatic Cancer;   Stage IIB Rectal Cancer;   Stage IIB Uterine Sarcoma;   Stage IIC Colon Cancer;   Stage IIC Ovarian Epithelial Cancer;   Stage IIC Ovarian Germ Cell Tumor;   Stage IIC Rectal Cancer;   Stage III Bladder Cancer;   Stage III Pancreatic Cancer;   Stage III Renal Cell Cancer;   Stage III Urethral Cancer;   Stage IIIA Cervical Cancer;   Stage IIIA Colon Cancer;   Stage IIIA Gastric Cancer;   Stage IIIA Ovarian Epithelial Cancer;   Stage IIIA Ovarian Germ Cell Tumor;   Stage IIIA Rectal Cancer;   Stage IIIA Uterine Sarcoma;   Stage IIIB Cervical Cancer;   Stage IIIB Colon Cancer;   Stage IIIB Gastric Cancer;   Stage IIIB Ovarian Epithelial Cancer;   Stage IIIB Ovarian Germ Cell Tumor;   Stage IIIB Rectal Cancer;   Stage IIIB Uterine Sarcoma;   Stage IIIC Colon Cancer;   Stage IIIC Gastric Cancer;   Stage IIIC Ovarian Epithelial Cancer;   Stage IIIC Ovarian Germ Cell Tumor;   Stage IIIC Rectal Cancer;   Stage IIIC Uterine Sarcoma;   Stage IV Bladder Cancer;   Stage IV Gastric Cancer;   Stage IV Ovarian Epithelial Cancer;   Stage IV Ovarian Germ Cell Tumor;   Stage IV Pancreatic Cancer;   Stage IV Renal Cell Cancer;   Stage IV Urethral Cancer;   Stage IVA Cervical Cancer;   Stage IVA Colon Cancer;   Stage IVA Rectal Cancer;   Stage IVA Uterine Sarcoma;   Stage IVB Cervical Cancer;   Stage IVB Colon Cancer;   Stage IVB Rectal Cancer;   Stage IVB Uterine Sarcoma;   Ureter Cancer
Interventions: Other: educational intervention;   Behavioral: telephone-based intervention;   Procedure: quality-of-life assessment;   Other: questionnaire administration
16 Recruiting Comparison Between Invasive Pressure Flow Study and Non-invasive Penile Cuff Test
Conditions: Bladder Outlet Obstruction;   Pressure Flow Study
Intervention:
17 Not yet recruiting Muscle Derived Cell Therapy for Bladder Exstrophy Epispadias Induced Incontinence
Conditions: Bladder Exstrophy;   Urinary Incontinence
Intervention: Drug: MDC
18 Recruiting Mecillinam for Treatment of Genital Chlamydia Infection
Conditions: Chlamydia Trachomatis Infection;   Chlamydial Urethritis
Intervention: Drug: Pivmecillinamhydrochlorid
19 Unknown  The Role of microRNAs in Organ Remodeling in Lower Urinary Tract Dysfunction
Conditions: Prostatic Hyperplasia;   Urinary Bladder Neck Obstruction;   Cystitis, Interstitial
Intervention:
20 Recruiting Diagnosis of Urethral Stricture With Sono-urethrography vs Conventional Urethrography (SONO-URETHRA)
Condition: Urethral Stricture Disease
Interventions: Radiation: Urografin 30%;   Radiation: NaCl 0,9 % in aqua

Indicates status has not been verified in more than two years